Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

KalVista Pharmaceuticals (KALV) Operating Expenses: 2014-2025

Historic Operating Expenses for KalVista Pharmaceuticals (KALV) over the last 7 years, with Apr 2025 value amounting to $45.8 million.

  • KalVista Pharmaceuticals' Operating Expenses fell 5.46% to $45.8 million in Q2 2025 from the same period last year, while for Apr 2025 it was $171.6 million, marking a year-over-year increase of 57.91%. This contributed to the annual value of $188.0 million for FY2025, which is 33.86% up from last year.
  • According to the latest figures from Q2 2025, KalVista Pharmaceuticals' Operating Expenses is $45.8 million, which was up 3.61% from $44.2 million recorded in Q3 2024.
  • KalVista Pharmaceuticals' 5-year Operating Expenses high stood at $48.5 million for Q2 2024, and its period low was $33.2 million during Q1 2024.
  • Its 2-year average for Operating Expenses is $42.9 million, with a median of $45.0 million in 2024.
  • Data for KalVista Pharmaceuticals' Operating Expenses shows a maximum YoY dropped of 5.46% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows KalVista Pharmaceuticals' Operating Expenses stood at $44.2 million in 2024, then declined by 5.46% to $45.8 million in 2025.
  • Its Operating Expenses stands at $45.8 million for Q2 2025, versus $44.2 million for Q3 2024 and $48.5 million for Q2 2024.